The fibroblasts growth factor 21 study in patients with non-alcoholic fatty liver disease and hypertension comorbidities


  • O. Ya. Babak Kharkiv National Medical University, Ukraine,
  • K. A. Lapshyna Kharkiv National Medical University, Ukraine,



non-alcoholic fatty liver disease, hypertension, liver fibrosis, fibroblast growth factor-21



The purpose of the study was to evaluate the fibroblast growth factor 21 levels (FGF-21) in blood plasma and the liver parenchyma state in non-alcoholic fatty liver disease (NAFLD) patients with hypertension.

Materials and methods. 60 NAFLD patients aged 30 to 60 years were examined. The average age of the patients was (50.1 ± 6.9) years. The control group consisted of 20 practically healthy volunteers. All the patients were diagnosed with NAFLD, traditionally examined by clinical and laboratory methods, assessed for trophological status and lipid metabolism. The determination of FGF-21 was performed by the immune enzyme method in blood plasma using ELISA kits.

Results. Evaluation of the liver parenchyma state demonstrated that in patients with NAFLD and hypertension, the F2-3 stage of fibrosis predominated in 60 % of cases. Depending on the existing stage of fibrosis, there was an increase in the liver enzymatic activity (P < 0.05, except the comparison results in patients with F0 and F1 stages), lipid profile (P < 0.001) and HOMA index (P < 0.05). An increase in the level of FGF-21 was detected in all NAFLD patients with hypertension and 3.4 times (P = 0.001) exceeded the parameters of practically healthy persons as well as its dependence on the stage of the liver fibrotic changes (P < 0.05, except the comparison results in patients with F1 and F2-3 stages). The correlations revealed confirm the pathogenetic relationship between FGF-21 and the liver inflammation development (P < 0.05).

Conclusions. The FGF-21 levels in the blood plasma of NAFLD patients with hypertension exceed the parameters of the control group, are higher with increasing degree of liver fibrosis and associated with metabolic disorders in patients. The results obtained characterize the cytokine FGF-21 as a promising predictor marker for NAFLD progression.



Denisov, N. L., Grinevich, V. B., Chernetsova, Ye. V., Kravchuk, Yu. A., & Ivashkin, K. V. (2017). Rol' nealkogol'noi zhirovoi bolezni pecheni v formirovanii ateroskleroticheskogo porazheniya sosudistoi stenki u patsientov s abdominal'nym ozhireniem [The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii, 27(1), 62-71. [in Russian].

Barb, D., Bril, F., Kalavalapalli, S., & Cusi, K. (2019). Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 104(8), 3327-3336.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO). (2016). Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts, 9(2), 65-90.

He, L., Deng, L., Zhang, Q., Guo, J., Zhou, J., Song, W., & Yuan, F. (2017). Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. BioMed Research International, 2017, Article 9729107.

Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X., Zhang, H., Pan, X., Bao, Y., Xiang, K., Xu, A., & Jia, W. (2010). Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal Of Hepatology, 53(5), 934-940.

Santoro, N., & Caprio, S. (2014). Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in obese adolescents: A looming marker of cardiac dysfunction. Hepatology, 59(2), 372-374.

Semba, R. D., Sun, K., Egan, J. M., Crasto, C., Carlson, O. D., & Ferrucci, L. (2012). Relationship of Serum Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance: The Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology & Metabolism, 97(4), 1375-1382.

Stein, S., Stepan, H., Kratzsch, J., Verlohren, M., Verlohren, H.-J., Drynda, K., Lössner, U., Blüher, M., Stumvoll, M., & Fasshauer, M. (2010). Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism, 59(1), 33-37.

Sung, K.-C., Wild, S. H., & Byrne, C. D. (2014). Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. Journal of Hepatology, 60(5), 1040-1045.

Trebicka, J., & Schierwagen, R. (2016). Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Read-out or reason? Hepatology, 63(5), 1729-1732.

Valva, P., De Matteo, E., Galoppo, M. C., Gismondi, M. I., & Preciado, M. V. (2010). Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. Journal of Medical Virology, 82(6), 949-957.

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.

How to Cite

Babak OY, Lapshyna KA. The fibroblasts growth factor 21 study in patients with non-alcoholic fatty liver disease and hypertension comorbidities. Zaporozhye Medical Journal [Internet]. 2020Apr.13 [cited 2024Jul.17];22(2). Available from:



Original research